OWP
ALXN

Obermeyer Wealth Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Obermeyer Wealth Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-150
Closed -$14K – 310
2013
Q2 		$14K Buy
+150
New +$14.5K ﹤0.01% 240

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Obermeyer Wealth Partners's ALXN Position: Q3 2013 in Review

Obermeyer Wealth Partners sold out of Alexion Pharmaceuticals (ALXN) in Q3 2013, closing a stake of 150 shares — an estimated $14K sold.

Obermeyer Wealth Partners first reported a position in ALXN in Q2 2013 and held it in 1 quarter. The position peaked at $14K in Q2 2013. 437 funds tracked by Wall St. Rank hold ALXN as of Q3 2013.

  • Obermeyer Wealth Partners reported no remaining Alexion Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Obermeyer Wealth Partners sold 150 Alexion Pharmaceuticals shares in Q3 2013, an estimated $14K.
  • Obermeyer Wealth Partners first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Obermeyer Wealth Partners's Alexion Pharmaceuticals position peaked at $14K in Q2 2013.
  • 437 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2013.

Based on Obermeyer Wealth Partners's 13F filing for Q3 2013, filed 18 Oct 2013.